通过将溶解数据纳入PBPK建模中,确定欧美普拉肠涂层囊的虚拟生物等价性和临床相关规范
Ruwei Yang1, Yaqi Lin1, Kaifeng Chen1
1Department of Pharmacy, The Third Xiangya Hospital, Central South University, Changsha, China.
The AAPS journal
|July 12, 2024
概括
这项研究开发了基于生理学的药理动力学 (PBPK) 模型和虚拟生物等价性 (VBE) 方法,用于肠膜涂层梅囊. 这些模型为通用欧米醇建立了临床相关的溶解规格,可能为BCSII类药物提供生物豁免.
科学领域:
- 药物动力学和生物制药学
- 药品开发和监管科学 药品开发和监管科学
背景情况:
- 生物制药品分类系统 (BCS) 的I和III类目前是立即释放的固体口服剂型的唯一豁免.
- 通过使用经过验证的建模的虚拟生物等价性 (VBE) 研究,BCS II类药物可能有资格获得生物豁免.
- 肠膜涂层的奥梅普拉尔囊提供了一个应用VBE到BCSII类仿制品的案例.
研究的目的:
- 建立基于生理学的药理动力学 (PBPK) 模型,体外-体内关系 (IVIVR) 和肠外涂层梅囊的VBE模型.
- 定义临床相关的溶解规范 (CRDS) 用于选生物等价性 (BE) 和非BE批量.
- 制定通用欧梅普拉肠涂层囊的评估标准,并探索BCSII类药物的生物豁免途径.
主要方法:
- 使用体外溶解数据和体外临床试验开发PBPK模型和IVIVR对梅.
- 应用VBE研究来确定生物等价性研究所需的样本大小.
- 建立基于特定时间点的体外溶解概况的CRDS.
主要成果:
- 预测的药理动力学 (PK) 概况和参数与观察到的PK数据密切匹配,验证了PBPK模型.
- VBE的结果表明,对于欧梅普拉肠涂层囊生物等价性研究,至少需要48名健康的中国受试者.
- 拟议的CRDS要求体外溶解量在2小时内不超过28%-54%,在3小时内不超过52%,在6小时内不超过80%.
结论:
- PBPK建模和IVIVR成功地将体外溶解与体内PK相结合,为梅肠涂层囊建立了生物等效安全空间.
- 开发的战略为评估BCSII类仿制药提供了一个框架,可能导致生物豁免和加速药物开发.
- 这项研究证明了通用药物开发的可行方法,减少了对广泛临床试验的需求.
相关概念视频
Bioequivalence: Overview
975
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
975
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
37
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
A recent model describes pravastatin's hepatobiliary excretion,...
37
Factors Affecting Dissolution: Drug pKa, Lipophilicity and GI pH
1.3K
Drug absorption within the gastrointestinal (GI) tract is a complex process influenced by several critical factors, including the site pH, the drug's dissociation constant (pKa), and the drug's lipophilicity. The GI tract exhibits a pH gradient, with an acidic environment in the stomach and a more alkaline environment in the small intestine. This pH variation directly affects the ionization state of drugs.
A drug's pKa and the pH of the gastrointestinal (GI) tract play crucial roles...
A drug's pKa and the pH of the gastrointestinal (GI) tract play crucial roles...
1.3K
Factors Influencing Drug Absorption: Drug Dissolution
459
The pharmacokinetic journey of drugs from solid oral dosage forms into systemic circulation is multifaceted. It begins with disintegration, a prerequisite ensuring a solid dosage form's subdivision into minute particles. Dissolution occurs next as these granulated entities solubilize in gastrointestinal fluids. This solubilization is crucial for the succeeding stage, permeation, which describes the traversal of the drug across the intestinal membrane and its subsequent entry into the blood...
459
Factors Affecting Dissolution: Drug Permeability, Stability and Stereochemistry
193
Orally administered drugs primarily enter the systemic circulation via passive diffusion through the intestinal membranes. The drug's absorption is influenced by drug stability in the gastrointestinal GI tract, membrane permeability, the surface area available for absorption, luminal drug concentration, and residence time in the lumen. Drug permeability can be enhanced by adjusting the lipophilicity, polarity, or molecular size of the drug, promoting its passive transport across intestinal...
193
One-Compartment Open Model for IV Bolus Administration: Estimation of Elimination Rate Constant, Half-Life and Volume of Distribution
237
The one-compartment open model is a simplified approach used in pharmacokinetics to understand the distribution and elimination of a drug administered through an intravenous bolus. This model assumes rapid drug dispersal throughout the body and elimination using a first-order process. Key pharmacokinetic parameters, such as the elimination rate constant (k), half-life (t1/2), and the apparent volume of distribution (Vd), can be estimated from this model. The elimination rate is calculated...
237


